RAPP | Ticker Profile - Titan Protect

RAPP

Rapport Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$36.10

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.9B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-8.84

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-28.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$56.00

+55% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 10 analysts covering this stock

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

https://www.rapportrx.com

Country: United States Employees: 84 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.765

Good returns relative to risk taken

Kelly Fraction

0.0752

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.512

Acceptable balance between returns and drawdown risk

Annual Return

38.7%

Historical annualised return based on price data

Max Drawdown

-75.5%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

161

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$42.27

15% below the year high

52W Low

$7.73

367% above the year low

Avg Volume

344,929

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

8.0%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.60

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.29

Heavy leverage — higher financial risk if revenues decline

Current Ratio

27.08

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

26.64

Like current ratio but excludes inventory — stricter test

Gross Margin

34.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-121.1%

Profit from core operations before interest and tax

Free Cash Flow

$-49,431,752

Negative — the business is spending more than it generates

Revenue (TTM)

$20M

Total revenue over the last 12 months

Net Income

$-107,277,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$80.00

Target Median

$56.00

Target Low

$40.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go